Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Scientists discover new mechanism that controls egg cell fertility

Scientists in Mainz and Aachen have discovered a new mechanism that controls egg cell fertility and that might have future therapeutic potential.

25 Apr 2013

Serum C-peptide levels predict cardiovascular death risk

Levels of C-peptide predict the risk for death from cardiovascular disease in nondiabetic adults, show data from the US National Health and Nutrition Examination Survey.

25 Apr 2013

Mechanism of tumor suppressor p53 inactivation described

Cancer cells are a problem for the body because they multiply recklessly, refuse to die and blithely metastasize to set up shop in places where they don’t belong. One protein that keeps healthy cells from behaving this way is a tumor suppressor named p53. This protein stops potentially precancerous cells from dividing and induces suicide in those that are damaged beyond repair. Not surprisingly, p53’s critical function is disrupted in most cancers.

25 Apr 2013

MRSA spotted on small US pig farms

Routine surveillance at small pig farms may be necessary, say researchers who identified both human and animal serum samples colonized with methicillin-resistant Staphylococcus aureus at such locations.

25 Apr 2013

Omeros presents clinical data of OMS302 on reducing pupil constriction during ILR at ASCRS meeting

Omeros Corporation today reported analyses of Phase 2 and Phase 3 clinical data showing the favorable impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement.

25 Apr 2013

Microglia guard nerve cells and play important role in their basic function

Researcher Johan Jakobsson and his colleagues have now published their results in Nature Communications.

25 Apr 2013

MCCIR scientists use video imaging to investigate effectiveness of rituximab in killing cancerous B cells

Scientists from the Manchester Collaborative Centre for Inflammation Research have discovered why a particular cancer drug is so effective at killing cells.

From The University of Manchester 25 Apr 2013

FDA designates Merck's lambrolizumab as Breakthrough Therapy for advanced melanoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma.

25 Apr 2013

Packard Children's recognized for leadership in health care food service

Lucile Packard Children's Hospital at Stanford has been honored with the "Food, Climate, Health Connection Award" from the Health Care Without Harm Healthy Food in Health Care program.

25 Apr 2013

Astrocytes more effective in promoting recovery after brain injury

The production of a certain kind of brain cell that had been considered an impediment to healing may actually be needed to staunch bleeding and promote repair after a stroke or head trauma, researchers at Duke Medicine report.

25 Apr 2013

Individuals with MEN1 are at increased risk of developing neuroendocrine tumors

A mutation in a protein called menin causes a hereditary cancer syndrome called MEN1 (multiple endocrine neoplasia type 1).

25 Apr 2013

Individual hydroxymethylcytosine molecules in DNA detected by new method involving chemical modification and nanopore analysis

Changes in the bases that make up DNA act as markers, telling a cell which genes it should read and which it shouldn’t. In the journal Angewandte Chemie, a British team has now introduced a new method that makes it possible to enrich the rare gene segments that contain the modified base hydroxymethylcytosine and to identify individual hydroxymethylcytosine molecules in DNA. Such modifications are associated with autoimmune diseases and cancer.

24 Apr 2013

Promising development for women with triple-negative breast cancer

Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary activities so that it might work on more aggressive breast cancer.

24 Apr 2013

Research maps risk factors for transmission of animal brucellosis, BTB to humans

A new study at the Institute of Tropical Medicine in Antwerp analyses the impact of animal brucellosis and bovine tuberculosis on animals and people in urban, peri-urban and rural Niger.

24 Apr 2013

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.

24 Apr 2013

Study identifies malaria parasite protein as potential new target for drug treatment to prevent malaria

Scientists have discovered how a protein within the malaria parasite is essential to its survival as it develops inside a mosquito. They believe their findings identify this protein as a potential new target for drug treatments to prevent malaria being passed to humans.

24 Apr 2013

Researchers studying lipids to learn more about normal, abnormal biology

When you have your cholesterol checked, the doctor typically gives you levels of three fats found in the blood: LDL, HDL and triglycerides. But did you know your body contains thousands of other types of fats, or lipids?

24 Apr 2013

Investigational treatment for ALS passes early phase clinical trial for safety

An investigational treatment for an inherited form of Lou Gehrig's disease has passed an early phase clinical trial for safety, researchers at Washington University School of Medicine in St. Louis and Massachusetts General Hospital report.

24 Apr 2013

Isis Pharmaceuticals starts ISIS-SMNRx Phase 2 study in infants with SMA

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy. SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of infant mortality.

24 Apr 2013

Researchers uncover potential new way to fight obesity-related illness

A potential new way to fight obesity-related illness has been uncovered, thanks to serendipitous research led by investigators at the Case Western Reserve University School of Medicine.

24 Apr 2013